News

Roche implements risk-mitigation plan for taspoglutide

BY Alaric DeArment

PARIS Swiss drug maker Roche has started a risk-mitigation plan in the late-stage clinical trial of an investigational diabetes drug due to some patients having bad reactions to it, the company’s development partner said Friday.

Ipsen announced the plan for the phase 3 trial of taspoglutide, a once-weekly treatment for Type 2 diabetes that belongs to class known as glucagon-like peptide-1 analogues. Other GLP-1 analogues include Novo Nordisk’s Victoza (liraglutide) and Byetta (exenatide), by Eli Lilly, Amylin Pharmaceuticals and Alkermes.

Among the more than 6,000 patients enrolled in phase 3 studies of taspoglutide, hypersensitivity reactions have remained uncommon, but are higher than expected, Ipsen said. Reactions have included skin and gastrointestinal symptoms, though patients have recovered without complications. Nevertheless, in light of the reactions, Roche has consulted with the Food and Drug Administration and decided to implement a risk-mitigation plan to identify patients at potential risk of the reactions.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

News

RSVP Group names Hayes Reilly as principal

BY Allison Cerra

EWING, N.J. A global human resources and management consultancy firm has appointed a new principal, the company announced this week.

In his new role, Hayes Reilly will have special responsibility for the fast-moving consumer goods and consumer healthcare products industries at the RSVP Group. Reilly will aid RSVP’s North American business while also significantly adding to its global reach, the company said.

Reilly has more than 12 years of experience in the retained executive search industry, with roles at top global firms in addition to founding his own, as well as 15 years of sales and marketing management experience with FMCG industries with roles at such companies as Unilever.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

News

Kinney Drugs promotes Burgess, hires former Duckwall-Alco SVP

BY Alaric DeArment

GOUVERNEUR, N.Y. Kinney Drugs has promoted 31-year veteran Michael Burgess to VP financial planning and treasury services, the retail pharmacy chain said Friday.

Kinney, which operates stores in central and northern New York state and Vermont, also hired Jim Spencer as director of retail operations.

Burgess will be responsible for the oversight of the corporate budget and capital spending that will direct financial and budgeting practices, managing corporate cash functions, treasury and accounting activity while continuing to provide strategic analysis and management of insurance and financial risk management programs.

Spencer will be responsible for front-end store operations. He has worked in the retail industry for 20 years, working for Walmart and, most recently, Duckwall-Alco Stores, where he was SVP operations.

“Mike and Jim’s industry experience will complement our mission of providing the highest quality pharmacy, health and retail services to the communities we serve,” Kinney president and COO Bridget-ann Hart said. “We will continue to benefit from Mike’s expertise while welcoming Jim’s retail proficiencies to the Kinney family.”

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES